Katy Grissom has extensive experience in financial analysis and consulting within the pharmaceutical and animal health sectors, having held roles at Eli Lilly and Company and Elanco. Notably, Katy worked as a Consultant in the Diabetes Business Unit and as an Analyst at the Lilly China Research & Development Center, where project management support was provided for financial and operational aspects of a new legal entity. Previous positions include leading risk evaluations in Corporate Audit Services and contributing to global strategy and operations at Elanco. Additionally, Katy served in investor relations and as a financial analyst at Eli Lilly, supporting research and development efforts. Educational qualifications include an MBA from Duke University and a Bachelor's degree in Finance and Operations Management from Indiana University Bloomington.
This person is not in the org chart
This person is not in any teams
This person is not in any offices